Abstract: The present invention provides a method of tissue healing in a subject involving administering to the subject a pharmaceutical composition for healing tissue. The pharmaceutical composition contains: adherent cells originating from mesenchymal tissue that has been treated with a physiologically active polypeptide or an LPS; and a pharmaceutically acceptable carrier.
Type:
Application
Filed:
July 15, 2021
Publication date:
November 4, 2021
Applicants:
OSAKA AIR MACHINE SERVICE, LTD., Regene Pharm Co., Ltd.
Abstract: Provided are a combination including glucagon and a compound or substance with therapeutic activity against a metabolic syndrome and a use thereof.
Type:
Application
Filed:
October 4, 2019
Publication date:
November 4, 2021
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Jung Kuk KIM, Young Jin PARK, In Young CHOI, Sang Don LEE, Jong Suk LEE
Abstract: An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent. A method of preparing an oral solid formulation includes forming granules containing irinotecan or a pharmaceutically acceptable salt thereof, a diluent, and a binder, mixing the granules with a disintegrant and a lubricant to obtain a mixture, and includes adding an acidifying agent in step of forming granules and/or mixing the granules.
Type:
Application
Filed:
July 8, 2021
Publication date:
October 28, 2021
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Caleb Hyung Min PARK, Myeong Ki JUNG, Jin Cheul KIM, Yong Il KIM, Jae Hyun PARK, Jong Soo WOO
Abstract: Provided is an oral pharmaceutical formulation including sustained-release pellets containing tamsulosin hydrochloride and a pharmaceutically acceptable additive, wherein the sustained-release pellets includes about 50 wt % to about 100 wt % of particles having a particle size of about 0.50 mm to about 0.85 mm, and less than about 15 wt % of particles having a particle size less than about 0.50 mm. The oral pharmaceutical formulation may have a reduced deviation in dissolution rate of tamsulosin hydrochloride and improved content uniformity among unit dosage forms, and have ensured quality due to high reproducibility of unit dosage forms.
Type:
Application
Filed:
July 14, 2017
Publication date:
October 21, 2021
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Hyung Seo KIM, Jung Hyun CHO, Jin Cheul KIM, Yong II KIM, Jae Hyun PARK, Jong Soo WOO
Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified Cl inhibitor, and administering complement inhibitor in combination with other therapeutics.
Type:
Application
Filed:
April 19, 2021
Publication date:
October 21, 2021
Applicant:
Pharming Intellectual Property B.V.
Inventors:
Bruno GIANNETTI, Jürgen SCHAALE, Anurag RELAN
Abstract: A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
October 19, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Sung Youb Jung, Yong Ho Huh, Sung Hee Park, Jong Soo Lee, In Young Choi
Abstract: The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
October 19, 2021
Assignees:
INSTITUT PASTEUR KOREA, ST PHARM CO., LTD.
Inventors:
Ji Young Min, So Young Chang, Ji Hye Lee, Sun Hee Kang, Sun Ju Kong, Su Yeon Jo, Young Mi Kim, Junghwan Choi
Abstract: The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.
Type:
Grant
Filed:
December 27, 2018
Date of Patent:
October 12, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.
Type:
Grant
Filed:
December 30, 2015
Date of Patent:
October 5, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Jung Kuk Kim, Jong Min Lee, Sang Yun Kim, Sung Min Bae, Sung Youb Jung, Se Chang Kwon
Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.
Abstract: An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent.
Type:
Grant
Filed:
June 20, 2016
Date of Patent:
August 17, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Caleb Hyung Min Park, Myeong Ki Jung, Jin Cheul Kim, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
Abstract: The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition comprising adherent cells originating from mesenchymal tissue treated with a physiologically active polypeptide or an LPS, or culture supernatant thereof, and a pharmaceutically acceptable carrier, and a method for producing the pharmaceutical composition.
Type:
Application
Filed:
June 17, 2019
Publication date:
August 12, 2021
Applicants:
OSAKA AIR MACHINE SERVICE, LTD., Regene Pharm Co., Ltd.
Abstract: A pharmaceutical composition for preventing or treating inflammatory disease comprising snake venom is disclosed. More specifically, the pharmaceutical composition or quasi-drug includes venom of Agkistrodon piscivorus piscivorus or Naja melanoleuca as an active ingredient. A method for preventing or treating inflammatory disease includes administering the venom of Agkistrodon piscivorus piscivorus or Naja melanoleuca to a subject. The composition can increase the expression of C-C chemokine receptor type 1 (CCR1) in a mouse where skin ulcer is induced and thus has an excellent effect of treating skin ulcers, and thus can be effectively used for the treatment of skin ulcers, in particular Behcet's disease or Buerger's disease.
Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
July 27, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.
Type:
Grant
Filed:
September 8, 2017
Date of Patent:
July 27, 2021
Assignee:
BEIJING HANMI PHARM. CO., LTD.
Inventors:
Nanmeng Song, Jiawang Liu, Yaping Yang, Yang Yang, Dongge Yang, Hongjuan Zhang, Mengxie Jin
Abstract: The present invention relates to a stevioside M crystal form, a preparation method therefor and a use thereof, and specifically, relates to a naturally extracted high-intensity sweetener, i.e., a stevioside M crystal form A, the preparation method therefor and the user thereof. By means of comprehensive characterization of the new crystal form, the new crystal form is found to have advantages such as a high degree of crystallinity, good stability, and low hygroscopicity, and is applicable to a more comprehensive field of application. The preparation method in the present invention is simple and easy to operate, has high selectivity and good reproducibility, and can stably obtain the target crystal form.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
July 13, 2021
Assignee:
ZHUCHENG HAOTIAN PHARM CO., LTD.
Inventors:
Liping Zhu, Xuefeng Mei, Ying Huang, Jianrong Wang
Abstract: The present invention provides ergostenol glycoside derivatives, method for preventing, treating, or alleviating dermatitis using the same. The present invention also provides a method for preparing the ergostenol and glycoside derivatives thereof. The ergostenol and the glycoside derivatives thereof according to the present invention suppress the production of chemokines increasing according to the skin inflammation stimulation and inhibit the activity of transcriptional factors controlling the expression of various inflammation mediators in the prevention and treatment of dermatitis.
Type:
Grant
Filed:
July 22, 2019
Date of Patent:
July 13, 2021
Assignee:
ST PHARM CO., LTD.
Inventors:
Hakwon Kim, Tae Hoon Lee, Hoongyu Park, Hyunjeong Oh
Abstract: Provided are a composite capsule and a method of preparing the composite capsule. The composite capsule includes a first dissolving part including a core, an inner coating layer on the core, and a first enteric coating layer on the inner coating layer, wherein core contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof. The composite capsule further includes a second dissolving part including a core, which contains, as an active ingredient, esomeprazole or a pharmaceutically acceptable salt thereof, an inner coating layer on the core, and a second enteric coating layer on the inner coating layer.
Type:
Grant
Filed:
October 19, 2017
Date of Patent:
July 6, 2021
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Taek Kwan Kwon, Seung Hun Chang, Ho Taek Im, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
July 6, 2021
Assignee:
ILDONG PHARM CO., LTD.
Inventors:
Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim